This tool also removes friction from the calculation process entirely
Approved medications can be widely distributed and prescribed by healthcare providers, ensuring that patients have access to effective treatments
What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium
Wegovy is the first once-weekly GLP-1 receptor agonist approved as a weight loss medication for people under the age of 18
Characterized by inflamed, boil-like bumps that can rupture and cause severe discomfort, HS can have a profound impact on daily life
Medicare: Does not cover either medication for weight loss under Part D (statutory exclusion of weight-loss drugs) Covers Mounjaro (tirzepatide for diabetes) and Ozempic (semaglutide for diabetes) under Part D Some Medicare Advantage plans cover Wegovy or Zepbound, but this is plan-specific Commercial insurance: Wegovy coverage: approximately 35% of commercial plans cover with prior authorization (as of Q1 2026) Zepbound coverage: approximately 28% of commercial plans cover with prior authorization Prior authorization typically requires documented BMI 30 (or 27 with comorbidity), previous weight-loss attempt, and prescriber attestation Cash prices (as of April 2026): Wegovy: $1,349 per month (list price) Zepbound: $1,059 per month (list price) Manufacturer savings programs reduce out-of-pocket costs for commercially insured patients but do not apply to Medicare, Medicaid, or uninsured patients in most states
